Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Calcineurin inhibitors Clear all
Completed No phase listed Observational Accepts healthy volunteers

Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents

NCT01678937
View directory record Official record
Conditions
Liver Transplant Rejection, Immunosuppression
Interventions
Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA, Blood Draw - Tacrolimus, Blood Draw - MMF
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Abatacept as GVHD Prophylaxis Phase 2

NCT01743131
View directory record Official record
Conditions
Graft vs Host Disease, Malignancy
Interventions
Abatacept, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Oakland, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 5, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

NCT01436305
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation
Interventions
Alemtuzumab, MMF, Basiliximab, Short-term Tac, tacrolimus, Belatacept, methylprednisolone
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 4 Interventional

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

NCT00352092
View directory record Official record
Conditions
Renal Transplant
Interventions
calcineurin inhibitor, sirolimus, mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

NCT01565616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Conditioning Regimen with Bone Marrow Transplant
Drug
Lead sponsor
Emory University
Other
Eligibility
16 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

NCT03527238
View directory record Official record
Conditions
Liver Transplant, Kidney Transplant
Interventions
PPM-based Computation Assisted Drug Dosing, Tacrolimus
Other · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

NCT01950819
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions
Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
98
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 5, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

NCT00117689
View directory record Official record
Conditions
Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
Interventions
Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 5, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

NCT00086346
View directory record Official record
Conditions
Liver Transplantation
Interventions
Sirolimus (Rapamune), Cyclosporine or Tacrolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
10
States / cities
San Francisco, California • Tampa, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 5, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

NCT04018937
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 13 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

NCT01379209
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Regimen, Allogeneic Bone Marrow Transplantation, Methotrexate, Mofetil Mycophenolate, sirolimus
Drug · Procedure
Lead sponsor
Regimmune Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Diego, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 5, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

NCT07566377
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease
Interventions
Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, Cyclosporine
Biological · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 26 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Belatacept in Heart Transplantation

NCT06478017
View directory record Official record
Conditions
Heart Transplant
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 71 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 5, 2026, 10:22 AM EDT
Completed No phase listed Observational

Evaluation of the Impact of Reduced Immunosuppression

NCT05238155
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
antimetabolite
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Recruiting Phase 4 Interventional

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT07611214
View directory record Official record
Conditions
Lupus Nephritis
Interventions
LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
Drug · Biological
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
27
States / cities
La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418
View directory record Official record
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 5, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 5, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345
View directory record Official record
Conditions
Kidney Transplant
Interventions
sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 5, 2026, 10:22 AM EDT